Nephros Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nephros Inc's ROI in the second quarter of 2026?
Nephros Inc achieved a return on average invested assets (ROI) of 15.31 % in its second quarter of 2026, which is below Nephros Inc's average return on investment, which stands at 176.06%.

ROI has improved compared to 7.15% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 69 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1186 to 1210.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	14.2 %	13.05 %	12.69 %	9.14 %	5.96 %
Y / Y Net Income Change TTM	30.82 %	-3.12 %	391.36 %	-	-
Investment (TTM) in Millions	12	11	11	11	10
Return On Investment (TTM)	15.31 %	7.15 %	11.27 %	14.39 %	13.37 %
NEPH's Overall Ranking	# 1210	# 1186	# 607	# 504	# 429
Seq. Investment Change TTM	4.51 %	2.38 %	2.98 %	3.66 %	3.45 %
Seq. Net Income Change TTM	123.71 %	-35.01 %	-19.38 %	11.61 %	65.67 %
Net Income (TTM) in Millions	2	1	1	1	1

NEPH Company Profile >> Back to NEPH Roi Comparisons >> See Annual NEPH Return On Investment

Return On Investment NEPH's Ranking
Within:	No.
Industry	# 14
Sector	# 70
Overall	# 1210

Return On Investment Statistics
High	Average	Low
16283.33 %	176.06 %	-818.09 %
(Dec 31 2013)		(Dec 31 2014)

Financial Statements
Nephros Inc's II. Quarter Investments	$ 12 Millions	NEPH's Balance sheet
Nephros Inc's II. Quarter Income	$ 1 Millions	Quarterly NEPH's Income Statement
NEPH's Income by Division		See NEPH's Income by Division

NEPH Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	11	10	10	13	18
Y / Y Investment Growth	12.71 %	-1.03 %	-24.29 %	-29.69 %	-7.46 %
Net Income in Millions	1	0	-2	-7	-4
Y / Y Net Income Growth	1513.51 %	-	-	-	-
Annual Return On Investment	10.98 %	0.77 %	-16.16 %	-55.19 %	-22.43 %

Annual Roi Comment

In the fiscal year 2025 ROI improved to 10.98 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NEPH's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NEPH's Competitors
Subscribers only: Roi for Nephros Inc's Suppliers
Subscribers only: Return On Investment for NEPH's Customers

Other Ratios
NEPH's Roa	NEPH's Inventory Turnover Ratio	NEPH's Growth Rates	NEPH's Dividend Statistics
	NEPH's Profitability Ratios	NEPH's Asset Turnover Ratio	NEPH's Dividend Growth
NEPH's Roe	NEPH's Valuation Ratios	NEPH's Financial Strength Ratios	NEPH's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector	ROI
Liquidia Corporation	42.09 %
Tg Therapeutics Inc	39.26 %
Medpace Holdings Inc	35.54 %
Mettler toledo International Inc	34.41 %
Eli Lilly And Company	33.95 %
Acadia Pharmaceuticals Inc	31.05 %
Caredx Inc	29.42 %
Adma Biologics Inc	28.94 %
Protalix Biotherapeutics inc	25.72 %
Pro dex Inc	24.29 %
Innoviva Inc	23.33 %
Electromed Inc	23.18 %
Zevra Therapeutics Inc	22.90 %
Iradimed Corporation	22.57 %
Alnylam Pharmaceuticals Inc	22.10 %
Eton Pharmaceuticals Inc	21.31 %
Dexcom Inc	20.98 %
Healthcare Services Group Inc	20.93 %
Arcutis Biotherapeutics Inc	20.77 %
Chemed Corporation	20.13 %
Resmed Inc	20.01 %
Halozyme Therapeutics Inc	19.99 %
Vertex Pharmaceuticals Inc	19.97 %
Agilent Technologies inc	19.84 %
Illumina Inc	19.61 %
Puma Biotechnology Inc	19.60 %
United Therapeutics Corporation	19.53 %
Zoetis Inc	19.44 %
Krystal Biotech Inc	19.16 %
Carlisle Companies Incorporated	18.88 %

Date modified: 2026-09-12T06:14:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.